Policy People In The News: Patrick Conway Departs CMS

Aug 17 2017

Listen to this article

Conway, a champion of the US agency's move into value-based care, will take the helm at Blue Cross/Blue Shield of North Carolina; Biogen, Astellas, Myovant make executive changes in policy operations.

The Center for Medicare and Medicaid Innovation is headed for new leadership with the upcoming departure of CMMI Director Patrick Conway. Conway, who also serves as deputy administrator for quality and innovation at the Centers for Medicare and Medicaid Services, will join Blue Cross and Blue Shield of North Carolina as president and CEO-elect on Oct. 1, the insurer announced Aug. 8.

Conway has been with CMS since 2011 and is the most senior, non-political executive at the agency. He first joined...

More from United States

COVID Vaccines: US FDA Changes Course, Wants New Formulas To Target KP.2 Subvariant ‘If Feasible’
Jan 05 2026
• By Sue Sutter
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
Diversity Action Plans: What To Submit And When
Apr 24 2025
• By Nielsen Hobbs
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
Stealth’s Elamipretide: Efficacy In Barth Syndrome Not Shown, US FDA Says
Oct 09 2024
• By Sue Sutter
Cardiovascular and Renal Drugs Advisory Committee will consider whether open-label extension data from a randomized trial that failed its primary endpoint, along with a historical control comparison, are enough to support approval in the ultra-rare disease.
New US FDA Adcomm Trend: Approved Cancer Meds Get Another Look When Competitors Coming
Oct 02 2024
• By Sarah Karlin-Smith
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.

More from North America

Stealth’s Elamipretide: Efficacy In Barth Syndrome Not Shown, US FDA Says
Oct 09 2024
• By Sue Sutter
Cardiovascular and Renal Drugs Advisory Committee will consider whether open-label extension data from a randomized trial that failed its primary endpoint, along with a historical control comparison, are enough to support approval in the ultra-rare disease.
New US FDA Adcomm Trend: Approved Cancer Meds Get Another Look When Competitors Coming
Oct 02 2024
• By Sarah Karlin-Smith
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
Clinical Trial Diversity Action Plans Need Timely FDA Feedback, Groups Say
Oct 02 2024
• By Sue Sutter
The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.